Evidence map›Paper›PMID 35272130›Full record

GuidelineESMO open2022

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

C Buske, M Dreyling, A Alvarez-Larrán, J Apperley, L Arcaini, C Besson, L Bullinger, P Corradini, M Giovanni Della Porta, M Dimopoulos and 26 more

Open access · goldAbstract readPractice GuidelineConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Guideline in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on Therapy.Mediterranean journal of hematology and infectious diseases · 2024
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 20 institutions in 13 countries.

C BuskeInstitute of Experimental Cancer Research, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany. Electronic address: christian.buske@uni-ulm.de.
M DreylingDepartment of Medicine III at LMU Hospital, Munich, Germany.
A Alvarez-LarránHematology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain.
J ApperleyCentre for Haematology, Imperial College London, Hammersmith Hospital, London, UK.
L ArcainiDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
C BessonService d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France; UVSQ, Inserm, CESP, Villejuif, France.
L BullingerDepartment of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
P CorradiniHematology Division, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
M Giovanni Della PortaCancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
M DimopoulosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
S D'SaUCLH Centre for Waldenström and Neurohaematology, University College London Hospitals NHS Foundation Trust, London, UK.
H T EichDepartment of Radiation Oncology, University of Muenster, Münster, Germany.
R FoàHematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
P GhiaStrategic Research Program on Chronic Lymphocytic Leukemia and Laboratory of B Cell Neoplasia, Division of Molecular Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.
M G da SilvaDepartment Of Hematology, Portuguese Institute of Oncology, Lisbon, Portugal.
J GribbenBarts Cancer Institute, Queen Mary University of London, London, UK.
R HajekDepartment of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
C HarrisonClinical Director - Haematology, Haemostasis, Palliative Care, Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
M HeuserDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany.
B KiesewetterDepartment of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
J J KiladjianUniversité de Paris, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, Paris, France.
N KrögerDepartment of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
P MoreauHematology Department, University Hospital Hotel-Dieu, Nantes, France.
J R PasswegHematology Division, Basel University Hospital, Basel, Switzerland.
F PeyvandiFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
D ReaUniversity Medical Department of Hematology and Immunology, France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Hôpital Saint-Louis, Paris, France.
J-M RiberaClinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
T RobakDepartment of Hematology, Medical University of Lodz, Lodz, Poland.
J F San-MiguelClínica Universidad de Navarra (CUN), Centro de Investigación Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC, Pamplona, Spain.
V SantiniMDS Unit, Hematology, DMSC, AOUC, University of Florence, Florence, Italy.
G SanzHematology Department, Hospital Univesitario y Politecnico La Fe, Valencia; CIBERONC, IS Carlos III, Madrid, Spain.
P SonneveldErasmus MC Cancer Institute, Department of Haematology, Rotterdam, The Netherlands.
M von Lilienfeld-ToalDepartment of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany; Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany.
C WendtnerMunich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany.
G PentheroudakisScientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland.
F PassamontiDepartment of Medicine and Surgery, University of Insubria, Varese, Italy. Electronic address: Francesco.Passamonti@asst-settelaghi.it.
University of Milan · ITCentre de recherche en Epidémiologie et Santé des Populations · FRCentre Hospitalier Universitaire de Nantes · FRCentro de Investigación Biomédica en Red de Cáncer · ESCharité - Universitätsmedizin Berlin · DEConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESErasmus MC Cancer Institute · NLEuropean Society for Medical Oncology · CHFondazione Humanitas per la Ricerca · ITGuy's and St Thomas' NHS Foundation Trust · GBHammersmith Hospital · GBHospital Base · CLInstituto Português de Oncologia Francisco Gentil · PTIstituti di Ricovero e Cura a Carattere Scientifico · ITJena University Hospital · DELaboratoire de Biologie Moléculaire et Cellulaire des Eucaryotes · FRLeibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) · DELMU Klinikum · DEMedical University of Lodz · PLMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group.

methodsThis consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. RESULTS AND

conclusionThe expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.

Indexed as

COVID-19Hematologic NeoplasmsConsensusCOVID-19 TestingHumansPandemicsconsensus manuscriptCOVID-19hematological malignancies

Identifiers

PMID35272130
PMCPMC8795783
OpenAlexW4210298192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.